CN117064776A

CN117064776A - Application of o-tolylmetformin or composition thereof in preparation of care product

Info

Publication number: CN117064776A
Application number: CN202311334017.6A
Authority: CN
Inventors: 黄继翔
Original assignee: Jinan Sarkoruide Biotechnology Co ltd
Current assignee: Jinan Sarkoruide Biotechnology Co ltd
Priority date: 2023-10-16
Filing date: 2023-10-16
Publication date: 2023-11-17
Anticipated expiration: 2043-10-16
Also published as: CN117064776B

Abstract

The invention relates to application of o-tolylmetformin or a composition thereof in preparing a care product. Skin and hair conditions are important factors affecting the extrinsic conditions of the person. The invention aims to provide an active compound with the effects of improving the skin aging state and promoting hair growth. Prior studies suggest that autophagy may be a key factor in improving skin condition and regulating hair growth cycle. The invention verifies that the o-tolylbiguanide is an autophagy activator, has the effects of reducing aging cells, enhancing autophagy, thereby improving the activity of hair follicle cells and promoting the growth of hair shafts, is hopeful to be applied to skin and scalp surface care products, and realizes the effects of resisting aging, growing and developing hair.

Description

Application of o-tolylmetformin or composition thereof in preparation of care product

Technical Field

The invention belongs to the technical field of skin and hair care products, and particularly relates to application of o-tolylmetformin or a composition thereof in preparation of skin and/or hair care products.

Background

The disclosure of this background section is only intended to increase the understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art already known to those of ordinary skill in the art.

Skin and hair are important factors affecting personal appearance instruments, are also important indexes affecting human health, and have important significance in developing compounds with skin care and hair growth promoting activities. There are studies showing that autophagy is an important factor affecting skin aging, and that autophagy activity of human skin decreases with age. The results of the local comparison show a significant decrease in autophagic activity in gray skin with age spots or associated with severe skin dryness relative to healthy skin. This suggests that reduced autophagy is associated with premature aging of human skin. The inhibition of autophagy by mTORC1 can significantly improve melanosome degradation and epidermal differentiation of human skin in vitro tissue culture, which suggests that autophagy plays an important role in maintaining various skin states such as skin barrier function and skin tone by controlling the integrity of melanosome degradation and epidermal differentiation. Thus, improving autophagy can act to improve skin aging. The Min Chai et al study shows that autophagy may be functionally related to hair growth, regulation of the hair follicle cell growth cycle, etc., and that metformin, as an autophagy inducer, promotes secretion of growth hormone, promoting hair from resting phase to growing phase. While currently autophagy activators suitable for skin care are still in the initial stage of the study, metformin has been demonstrated to have hair growth promoting effects but still belongs to the cosmetic disabling component (see cosmetic safety technical Specification 2015). It has also been reported that the application of rapamycin to human skin reduces stains and age spots, but rapamycin, as an immunosuppressant drug, has considerable side effects on cellular molecular signaling pathways and is less likely to be used as a skin care raw material. In view of the current state of development, the inventors believe that screening autophagy activators based on currently accepted cosmetic raw materials is of great importance for the development of skin care and skin condition improvement formulations, promoting hair growth and preventing hair loss formulations.

Disclosure of Invention

In view of the above-described state of development, the present invention was searched for "catalog of used cosmetic raw materials" version 2021, and it was considered that o-tolylbiguanide (CAS No. 93-69-6) might be a potential autophagy activator. The invention proves that the o-tolylbiguanide has the effect of promoting autophagy and can improve the activity of aging skin cells through cytotoxicity test of fibroblasts, in-vitro cell experiments and the like. In vitro culture of hair papilla cells and in vitro hair follicle tests prove that the o-tolylbiguanide has the effects of promoting cell activity and hair growth, and can be used for growing and developing hair and improving alopecia. The above studies indicate that o-tolylbiguanide can improve skin and hair condition by promoting cell autophagy mechanism, and is used as an effective raw material in personal care products.

Based on the technical effects, the invention provides the following technical scheme:

in a first aspect, there is provided a composition of o-tolylbiguanide comprising an active amount of o-tolylbiguanide.

The composition comprises an active dose of o-tolylbiguanide and other active ingredients; the meaning of the active dose is: based on the application mode of the composition, the composition can be applied to a subject to achieve the technical effects of slowing down skin aging, nourishing hair follicle cells, growing hair, preventing or even treating alopecia and the like, and the specific dosage value belongs to the technical content which can be directly determined according to the conventional research mode in the field.

The addition purposes of the other active ingredients include:

(1) Improving the water solubility of the o-tolylbiguanide;

(2) Enhancing the physiological activity of the composition;

(3) As an auxiliary material of the preparation.

In the above (1), the composition is composed of o-tolylbiguanide and 10 to 200 mol% of an organic acid, preferably one or a combination of several of citric acid, glycolic acid, lactic acid, hydroxybutyric acid, glutamic acid, aspartic acid, malic acid, tartaric acid, succinic acid, gluconic acid, lactobionic acid, maltobionic acid, mandelic acid and salicylic acid.

In the above (2), the other active ingredients are also autophagy promoters, including compound entities and natural compounds: examples of such compound entities are spermidine, spermidine salts, mono-or diamidated spermidine, one or more of the mono-to tri-ester compounds of hydroxycitric acid ((-) -Hydroxycitric acid), or plant extracts containing hydroxycitric acid, for example garcinia cambogia extract (Garcinia Combogia Extract); the natural compound is preferably liposome coated, such as resveratrol and its derivatives, berberine and its derivatives, procyanidine and its derivatives, curcumin and its derivatives, and epigallocatechin gallate.

Possible formulation auxiliary materials for the above aspect (3) include, but are not limited to, solvents, surfactants, lubricants, wetting agents, fragrances, emulsifiers, suspending agents, antistaling agents or carriers, etc.; specific examples of the solvent are water, ethanol, propylene glycol, and glycerol; specific examples of the surfactant are fatty alcohol sulfate, fatty alcohol ether sulfate, sulfosuccinic monoester, isethionate, imidazoline derivative, methyltaurate, sarcosinate, fatty acid amide ether sulfate, alkylamide betaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.

In a second aspect there is provided the use of o-tolylbiguanide or a composition according to the first aspect in the manufacture of a care product.

In the technical scheme of the aspect, the o-tolylbiguanide is a compound with a structure shown in a formula A or a salt of the compound:

formula A;

the above "salt of a compound" is a salt form used for increasing the solubility or stability of o-tolylbiguanide, and considering that the present invention mainly provides the use of o-tolylbiguanide in a care product, the salt form is preferably a salt of o-tolylbiguanide with an organic acid, which is an acid that allows addition to a care product, such as one of citric acid, glycolic acid, lactic acid, hydroxybutyric acid, glutamic acid, aspartic acid, malic acid, tartaric acid, succinic acid, gluconic acid, lactobionic acid, maltobionic acid, mandelic acid, salicylic acid.

The skin structure of human being is composed of external and internal epidermis layers and dermis layers, the surface of epidermis layer also has stratum corneum, which is composed of dead and flat keratinocytes, and the space between keratinocytes is filled with a multi-layer structure composed of water-double-layer phospholipids, which is called as a mud-brick model. However, for active ingredients or drugs, the barrier action of the stratum corneum is an obstacle that needs to be crossed before contacting living cells. Since keratinocytes have been killed and active ingredients cannot be transported by active transport proteins and the like, the active ingredients can only penetrate through the multi-layer alternately arranged water-phospholipid bilayer structure by means of concentration differences, the hydrophilic inner part of the surface of the phospholipid bilayer is hydrophobic, and the more lipophilic ingredients are easy to penetrate. The o-tolylbiguanide has a benzene ring group with higher lipophilicity than dimethylbiguanide, making it more lipophilic, the Log p of the theoretical calculated dimethylbiguanide (Log value of octanol-water partition coefficient, the greater the lipophilicity is), is-2.31, the Log p of the o-tolylbiguanide is 1.13, and the theoretical calculation considers that the concentration of the o-tolylbiguanide in the lipid phase is almost 1000 times that of dimethylbiguanide. The LogD-pH5.5 of both calculated as pH5.5 under consideration of the acidic environment of the skin surface, the metformin was-3.37 and the o-tolylbiguanide was-0.98, indicating that the concentration of o-tolylbiguanide in the lipid phase was still more than 200 times that of metformin at pH5.5. The great advantage of o-tolylbiguanide in lipophilicity makes it more suitable for external application to the skin.

The above care product is a care product acting on skin and/or hair, and has the main effects of improving the aging state of skin, promoting hair growth or preventing hair loss by increasing the level of autophagy; wherein the skin comprises scalp and body skin, preferably scalp, face, neck, hands, feet and other skin which may be exposed to the outside, or where improvement is desired; the hair is mainly hair; the treatment product may be applied by direct contact with the skin or hair surface or may be removed after resting on the skin or hair surface.

The types of care products applied to scalp or hair include, but are not limited to, conventional care products such as shampoo, hair mask, hair wax, hair care essential oil and the like, and hair growth products in the form of smearing or spraying; the types of care products applied to the face and neck include, but are not limited to, facial cleanser, facial soap, toner, milky lotion, cream, pack, facial mask, sun block, essence, foundation, concealer, and the like; the product acting on hands or feet can also be soap, hand cream, body lotion, hand cleanser, etc.

The invention also examines the safe concentration of the o-tolylbiguanide applied care product, and in an in vitro cell test, the o-tolylbiguanide is used at a concentration of 0.01-0.08 mg/ml, and the concentration of the o-tolylbiguanide applied care product is 10-50 times that of the cell test when the o-tolylbiguanide applied care product is used on the skin in consideration of the barrier and permeability of the stratum corneum of the skin. In addition, when o-tolylbiguanide is applied to in vitro culture of hair follicles, the use concentration of o-tolylbiguanide needs to be increased correspondingly in consideration of the fact that the culture medium is a solid medium containing agarose, the material diffusion rate is lower than that of a liquid medium used in a cell experiment, and the mass fraction of the verification of the present invention is 0.04%. Considering factors such as formula, human body difference, error and the like, the upper limit of the application range of the o-tolylbiguanide is considered to be 5mg/ml or 0.5% W/W; the preferable mass fraction range is 0.08% -0.5%, and more preferable is 0.1% -0.3%.

In a third aspect, there is provided a serum for use on a skin surface, the serum comprising the following components in mass fraction: betaine 0.7-1.1%, glycerol 2-4%, o-tolylbiguanide 0.08-0.12%, propylene glycol 1.5-2.5%, 1, 2-hexanediol 2-4%, citric acid to adjust pH to 5.0-6.0, and the balance water.

The preparation method of the essence comprises the following steps: the betaine, the glycerol, the o-tolylbiguanide, the propylene glycol and the 1, 2-hexanediol with the dosages are mixed in advance to obtain a mixed solution, the mixed solution is added into water to be completely dissolved, and then citric acid is slowly added to adjust the pH value of the solution to 5.0-6.0.

The essence product can be applied to skin surface, preferably exposed skin surface such as face, neck, and hand; when in use, the medicine is taken to the use part and fully absorbed.

In a fourth aspect, there is provided an essence for scalp care, the essence comprising the following components in mass fraction:

0.1-0.3% of L-arginine, 0.1-0.2% of L-glutamic acid, 0.03-0.07% of L-cysteine, 0.4-0.7% of inositol, 2-4% of glycerol, 0.08-0.12% of o-tolylbiguanide, 1-3% of propylene glycol, 2-4% of 1, 2-hexanediol, citric acid, and the balance of water.

The preparation method of the essence product comprises the following steps:

the preparation method comprises the steps of pre-mixing L-arginine, L-glutamic acid, L-cysteine, inositol, glycerol, o-tolylbiguanide, propylene glycol and 1, 2-hexanediol in a formula dosage to obtain a mixed solution, adding the mixed solution into water to completely dissolve the mixed solution, and then slowly adding citric acid to adjust the pH value of the solution to 5.0-6.0.

Drawings

The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the invention.

FIG. 1 is a graph showing the effect of o-tolylbiguanide on skin cell morphology as described in example 1;

wherein, fig. 1A is a blank control experiment group of keratinocytes;

FIG. 1B is a keratinocyte +0.0781mg/ml o-tolylbiguanide group cell morphology;

FIG. 1C is a keratinocyte +0.1563mg/ml o-tolylbiguanide group cell morphology;

FIG. 1D is a blank control of fibroblasts;

FIG. 1E is a fibroblast+0.0781 mg/ml o-tolylbiguanide group cell morphology;

FIG. 1F is a fibroblast+ 0.1563mg/ml o-tolylbiguanide group cell morphology;

FIG. 2 is the results of CCK8 experiments described in example 1;

the a-e experimental group is a cell viability result of normal fibroblasts (a), normal fibroblasts+0.01 mg/ml o-tolylbiguanide (b), normal fibroblasts+0.02 mg/ml o-tolylbiguanide (c), normal fibroblasts+0.04 mg/ml o-tolylbiguanide (d) and normal fibroblasts+0.08 mg/ml o-tolylbiguanide (e) in sequence; the f-j experimental group is the cell viability results of the aged fibroblasts (f), the aged fibroblasts+0.01 mg/ml o-tolylbiguanide (g), the aged fibroblasts+0.02 mg/ml o-tolylbiguanide (h), the aged fibroblasts+0.04 mg/ml o-tolylbiguanide (i) and the aged fibroblasts+0.08 mg/ml o-tolylbiguanide (j) in sequence;

FIG. 3 is a representative graph of the results of flow cytometric analysis described in example 1;

FIG. 4 is a histogram of the results of the flow cytometric analysis described in example 1;

FIG. 5 shows the results of SA-. Beta. -Gal staining microscopy described in example 1;

wherein, fig. 5A is a normal HFF cell group, stained cell number: 8+ -3.46;

FIG. 5B is D-gal aging HFF, stained cell count: 61±5.57;

FIG. 5C is D-gal aging HFF+o-tolylbiguanide, stained cell number: 12±4.36;

FIG. 6 shows the Western blot detection of Beclin1, LC 3I/II, p62 protein expression (GADPH as reference) of the respective groups of cells described in example 1;

FIG. 7 shows the effect of o-tolylbiguanide on hair papilla cells described in example 1;

FIG. 8 is a graph showing the effect of o-tolylbiguanide on hair follicles ex vivo as described in example 1;

wherein, fig. 8A is a photograph of hair follicle/hair shaft at blank control group 0 d;

fig. 8B is a photograph of hair follicle/hair shaft at 10d of the blank group;

fig. 8C is a photograph of hair follicle/hair shaft at 0d of o-tolylbiguanide group;

fig. 8D is a photograph of hair follicle/hair shaft at 10D of o-tolylbiguanide group.

Detailed Description

It should be noted that the following detailed description is illustrative and is intended to provide further explanation of the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of exemplary embodiments according to the present invention. As used herein, the singular is also intended to include the plural unless the context clearly indicates otherwise, and furthermore, it is to be understood that the terms "comprises" and/or "comprising" when used in this specification are taken to specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof.

In order to enable those skilled in the art to more clearly understand the technical scheme of the present invention, the technical scheme of the present invention will be described in detail with reference to specific embodiments.

Example 1

1. Skin cytotoxicity test of o-tolylbiguanide

1. Experimental materials

Human fibroblasts, lot Fb20081902 human keratinocytes, lot No.: ep220707, supplied by guangdong boshi biotechnology limited; DMEM broth (Gibco), kcGrowth broth (guangdong bosch organism), PBS (soribao), MTT (Sigma), DMSO (Sigma).

2. Experimental procedure

1) Cell inoculation: keratinocytes were measured at 1X 10 ⁴ Seeding Density of individual/well cells were seeded into 96 well plates with fibroblasts at 7X 10 ³ Cell/well seeding Density cells were seeded into 96 well plates, incubator (37 ℃, 5% CO) ₂ ) Incubate overnight.

2) Test grouping: the test set-up was zeroed, blank, positive control (10% dmso) and sample (o-tolylbiguanide). The sample set was set with 8 concentration gradients, with 3 replicate wells per concentration gradient.

3) Administration: and (5) administering when the cell plating rate in the 96-well plate reaches 40% -60%. 200 mu L of culture solution is added to each hole of the blank group; 200. Mu.L of culture medium containing 10% DMSO was added to each well of the positive control group; 200 mu L of culture solution containing samples with corresponding concentrations is added into each hole of the sample group; the zeroed group was inoculated without cells and only 200. Mu.L of cell culture medium was added. After completion of the administration, the 96-well plate was placed in an incubator (37 ℃ C., 5% CO) ₂ ) Is cultured for 24 hours.

4) And (3) detection: after the cells are incubated for 24 hours, the supernatant is discarded, 0.5mg/mL MTT working solution is added, the cells are incubated for 4 hours at 37 ℃ in a dark place, after the incubation is finished, 150 mu L DMSO is added to each well, and the OD value is read at 490 nm.

5) Cell relative viability calculation: cell relative viability (%) = (sample well OD-zeroed well OD)/(blank well OD-zeroed well OD) ×100%.

The test results showed that on both skin cells, o-tolylbiguanide cell viability was indistinguishable from the blank at 0.0781mg/ml, and the cell viability data and cell photographs for partial concentrations are shown in table 1, figure 1.

TABLE 1 influence of o-tolylbiguanide on cell viability (100% on blank)

2. Effect of o-tolylbiguanide on autophagy of fibroblasts

To verify the autophagy induction of the epidermal cells by o-tolylbiguanide, in this example, the following experiment was designed:

a cell senescence model was constructed using 10 g/L D-gal (D-galactose) to induce HFF cells (human skin fibroblasts, SCSP-106) 72 h. HFF cells were randomly divided into normal cells + vehicle control group, normal cells + dosing group, model cell + dosing group. After incubation for 24 hours with o-tolylbiguanide at final concentrations of 0.010, 0.020, 0.040, 0.080 mg/mL in the dosing group, cell viability was detected by CCK8 method and the results are shown in table 2, fig. 2, and the results of the experimental groups a-j shown in fig. 2 are shown in table 2 below:

TABLE 2 influence of o-tolylbiguanide concentration on cell viability

The results are reflected in accordance with table 2: in normal cells of groups a-e, cell viability did not show significant differences, and in senescent cells of groups f-j, viability was increased in proportion to concentration. In connection with the safety of use of o-tolylbiguanide in Table 1, the present example was chosen to continue testing at a concentration of 0.08 mg/ml. The cells are randomly divided into a blank control group, an aging model group and a drug treatment group, the autophagy condition of each group of cells is detected by MDC/PI flow cytometry, the aging condition of each group of cells is detected by SA-beta-Gal staining, and the expression condition of the Beclin1, LC 3I/II and p62 proteins of each group of cells is detected by Western blot.

The experimental results show that the autophagy of aged HFF cells can be remarkably improved in flow cytometry analysis (FIG. 3 and FIG. 4) by continuing the test at 0.08mg/ml, and the statistical results in FIG. 4 are shown in Table 3; color detection showed that o-tolylbiguanide culture significantly reduced the number of stained cells after a period of time after aging HFF (fig. 5), i.e., o-tolylbiguanide culture reduced the number of aged cells (fig. 5), and Western blot detection showed that o-tolylbiguanide culture increased Beclin1 expression, increased LC3 II/I ratio, and decreased p62 expression (fig. 6, table 4). From the above experimental results, it can be seen that o-tolylbiguanide has no effect on normal HFF activity at a concentration of 0.01-0.08 mg/ml, and can improve the activity of aging HFF cells and positively correlate with the concentration. O-tolylbiguanide is considered to increase autophagy of senescent cells, decrease the number of senescent cells, and is an anti-skin-aging active.

TABLE 3 Table 3

TABLE 4 Table 4

3. Effect of o-tolylbiguanide on papilla cells of hair follicle and hair growth of hair follicle ex vivo

Hair growth is periodic, in which hair loss in anagen phase is a direct factor causing alopecia, and its main reason is that hair papilla cells located at the bottom of hair follicle are weakened in activity due to apoptotic damage or the like, so that promotion of enhancement of hair papilla cell activity can achieve a certain anti-alopecia effect. In this example, hair papilla cells were divided into a control group and an experimental group, the control group was cultured in the same manner as the positive control group in the "toxicity test", and 0.08mg/ml o-tolylbiguanide was additionally added to the experimental group. The relative viability of the cells was measured by MTT method at intervals of 24hr with reference to 100% at 0hr in vitro culture of hair papilla cells of both experimental groups, and as shown in FIG. 7, 0.08mg/ml o-tolylbiguanide significantly improved hair papilla cell viability within 24-72 hr.

The growth cycle of hair is divided into three main phases of growth phase, catagen phase and telogen phase, wherein the anagen phase is the period of the most vigorous hair follicle growth, and the activation of cell autophagy can make the hair follicle enter the anagen phase. In vitro culture of mouse ex vivo hair follicles with 0.3% H ₂ O ₂ Treatment an in vitro hair loss model for oxidative stress injury was established, followed by treatment with 0.4mg/ml (0.04% w/w) o-tolylbiguanide, and inhibition of hair loss was determined by microscopic analysis of the length of the hair shaft and scoring of the hair follicle cycle after 10d of culture (control group hair follicle in vitro medium is agarose medium of DMEM, experimental group additionally added with 0.4mg/ml o-tolylbiguanide). The results show that the hair shaft length can be significantly improved after 0.4mg/ml o-benzyl biguanide treatment for 10d, as shown in fig. 8. O-tolylbiguanide has proven to be useful in hair care products as an active for improving hair loss and promoting hair growth.

TABLE 5

The following examples serve as illustrative illustrations of the care products described in the present invention:

example 2O-tolylbiguanide containing essence for skin care

In this example, a lotion product is provided for direct application to the skin surface, the ingredients and proportions of which are shown in table 6 below:

TABLE 6

The process comprises the following steps: and (3) mixing all the components in the phase A, adding the phase B, stirring until the components are dissolved, slowly dripping the phase C, and regulating the pH of the product to be within a range of 5.0-6.0 to obtain the finished product. The composition can be applied on skin. In this example, a serum was prepared in the specific proportions shown in table 7.

TABLE 7

The essence can be used after skin is cleaned, and the essence is taken to be properly smeared on the surface of the skin and is absorbed by massaging.

Example 3 essence containing o-tolylbiguanide for scalp care

In this embodiment, an essence product for scalp care is provided, which has effects of preventing and improving alopecia and promoting hair growth. The components and proportions of the product are shown in Table 8 below:

TABLE 8

The process comprises the following steps: and (3) mixing all the components in the phase A, adding the phase B, stirring until the components are dissolved, slowly dripping the phase C, and regulating the pH of the product to be within a range of 5.0-6.0 to obtain the finished product. When in use, the composition is applied to scalp with appropriate amount and is suitably massaged or rubbed. In this example, a serum was prepared in the specific proportions shown in table 9.

TABLE 9

The essence can be directly smeared on scalp for use, and can be absorbed by massaging.

The above description is only of the preferred embodiments of the present invention and is not intended to limit the present invention, but various modifications and variations can be made to the present invention by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. The use of o-tolylbiguanide or a composition thereof in the preparation of a care product, characterized in that said o-tolylbiguanide comprises a small molecular entity of the structure represented by formula a, and further comprises a salt of a compound of said structure:

formula A;

in the nursing product, the use mass fraction range of the o-tolylbiguanide is 0.08% -0.5%;

the salt of the compound is formed by o-tolylbiguanide and an organic acid, wherein the organic acid is selected from one of citric acid, glycolic acid, lactic acid, hydroxybutyric acid, glutamic acid, aspartic acid, malic acid, tartaric acid, succinic acid, gluconic acid, lactobionic acid, maltobionic acid, mandelic acid and salicylic acid;

the care product acts on skin and/or hair, is a product for improving skin aging, preventing hair loss or promoting hair growth;

o-tolylbiguanides improve skin and hair condition by promoting the mechanism of action of cell autophagy.

2. The use according to claim 1, wherein the treatment product acts in such a way as to be in direct contact with the skin surface or to be removed after resting on the skin surface;

the skin is scalp, face, neck, hand, foot and other exposed skin, or parts with improvement requirement;

the hair is hair.

3. The use according to claim 2, wherein the type of care product applied to the scalp is selected from the group consisting of shampoos, hair films, hair waxes, hair care essential oils or hair tonic products in the form of a spread or spray.

4. The use according to claim 2, wherein the type of care product applied to the face and neck is selected from self-cleaning creams, soaps, lotions, creams, facial patches, sunscreens, essences, foundations or concealers.

5. Use according to claim 2, wherein the product acting on the hands or feet is selected from soaps, hand creams, body milks or hand washes.

6. The use according to claim 1, wherein the composition comprises an active amount of o-tolylbiguanide, and further comprises an additional active ingredient; the other active ingredients are added for the following purposes:

(1) Improving the water solubility of the o-tolylbiguanide;

(2) Enhancing the physiological activity of the composition;

(3) As an auxiliary material of the preparation.

7. The use according to claim 6, wherein in aspect (1) the other active ingredient is an organic acid, the composition is a composition of o-tolylbiguanide and 10 to 200% by mole of an organic acid selected from one or more of citric acid, glycolic acid, lactic acid, hydroxybutyric acid, glutamic acid, aspartic acid, malic acid, tartaric acid, succinic acid, gluconic acid, lactobionic acid, maltobionic acid, salicylic acid.

8. The use according to claim 6, wherein in aspect (2) the other active ingredients comprise the compound entity and the natural compound: the compound entity is selected from one or more of spermidine, spermidine salt, monoamide or diamidated spermidine and monoester-triester compounds of hydroxycitric acid;

the natural compound is selected from one or more of resveratrol and its derivatives, berberine and its derivatives, procyanidine and its derivatives, curcumin and its derivatives, epigallocatechin gallate, and the natural compound adopts liposome coating.

9. An essence for skin surface, characterized in that the essence comprises the following components in the following doses: betaine 0.7-1.1%, glycerol 2-4%, o-tolylbiguanide 0.08-0.12%, propylene glycol 1.5-2.5%, 1, 2-hexanediol 2-4%, citric acid to adjust pH to 5.0-6.0, and the balance water.

10. An essence for scalp care, which is characterized by comprising the following components in doses: